Effects of IGF-1 on the cardiovascular system
Nema prikaza
Autori
Obradović, Milan M.Zafirović, Sonja
Soskić, Sanja S.
Stanimirović, Julijana
Trpković, Andreja
Jevremović, Danimir P.
Isenović, Esma R.
Članak u časopisu (Objavljena verzija)
,
© 2019 Bentham Science Publishers
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Cardiovascular (CV) diseases are the most common health problems worldwide, with a permanent increase in incidence. Growing evidence underlines that insulin-like growth factor 1 (IGF-1) is a very important hormone responsible for normal CV system physiology. IGF-1 is an anabolic growth hormone, responsible for cell growth, differentiation, proliferation, and survival. Despite systemic effects, IGF-1 exerts a wide array of influences in the CV system affecting metabolic homeostasis, vasorelaxation, cardiac contractility and hypertrophy, autophagy, apoptosis, and antioxidative processes. The vasodilatory effect of IGF-1, is achieved through the regulation of the activity of endothelial nitric oxide synthase (eNOS) and, at least partly, through enhancing inducible NOS (iNOS) activity. Also, IGF-1 stimulates vascular relaxation through regulation of sodium/potassium-adenosine-triphosphatase. Numerous animal studies provided evidence of diverse influences of IGF-1 in the CV system such as v...asorelaxation, anti-apoptotic and prosurvival effects. Human studies indicate that low serum levels of free or total IGF-1 contribute to an increased risk of CV and cerebrovascular disease. Large human trials aiming at finding clinical efficacy and outcome of IGF-1-related therapy are of great interest. We look forward to the development of new IGF 1 therapies with minor side effects. In this review, we discuss the latest literature data regarding the function of IGF-1 in the CV system in the physiological and pathophysiological conditions. © 2019 Bentham Science Publishers.
Ključne reči:
cardiovascular disease / cardiovascular system / IGF-1 / vasodilatory effect / anti-apoptotic effect / tissue restructuring effects / anti-aging effectsIzvor:
Current Pharmaceutical Design, 2019, 25, 35, 3715-3725Finansiranje / projekti:
- Hormonska regulacija ekspresije i aktivnosti azot oksid sintaze i natrijum-kalijumove pumpe u eksperimentalnim modelima insulinske rezistencije, dijabetesa i kardiovaskularnih poremećaja (RS-MESTD-Basic Research (BR or ON)-173033)
DOI: 10.2174/1381612825666191106091507
ISSN: 1381-6128
PubMed: 31692426
WoS: 000502328500003
Scopus: 2-s2.0-85076482879
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Obradović, Milan M. AU - Zafirović, Sonja AU - Soskić, Sanja S. AU - Stanimirović, Julijana AU - Trpković, Andreja AU - Jevremović, Danimir P. AU - Isenović, Esma R. PY - 2019 UR - https://vinar.vin.bg.ac.rs/handle/123456789/8483 AB - Cardiovascular (CV) diseases are the most common health problems worldwide, with a permanent increase in incidence. Growing evidence underlines that insulin-like growth factor 1 (IGF-1) is a very important hormone responsible for normal CV system physiology. IGF-1 is an anabolic growth hormone, responsible for cell growth, differentiation, proliferation, and survival. Despite systemic effects, IGF-1 exerts a wide array of influences in the CV system affecting metabolic homeostasis, vasorelaxation, cardiac contractility and hypertrophy, autophagy, apoptosis, and antioxidative processes. The vasodilatory effect of IGF-1, is achieved through the regulation of the activity of endothelial nitric oxide synthase (eNOS) and, at least partly, through enhancing inducible NOS (iNOS) activity. Also, IGF-1 stimulates vascular relaxation through regulation of sodium/potassium-adenosine-triphosphatase. Numerous animal studies provided evidence of diverse influences of IGF-1 in the CV system such as vasorelaxation, anti-apoptotic and prosurvival effects. Human studies indicate that low serum levels of free or total IGF-1 contribute to an increased risk of CV and cerebrovascular disease. Large human trials aiming at finding clinical efficacy and outcome of IGF-1-related therapy are of great interest. We look forward to the development of new IGF 1 therapies with minor side effects. In this review, we discuss the latest literature data regarding the function of IGF-1 in the CV system in the physiological and pathophysiological conditions. © 2019 Bentham Science Publishers. T2 - Current Pharmaceutical Design T1 - Effects of IGF-1 on the cardiovascular system VL - 25 IS - 35 SP - 3715 EP - 3725 DO - 10.2174/1381612825666191106091507 ER -
@article{ author = "Obradović, Milan M. and Zafirović, Sonja and Soskić, Sanja S. and Stanimirović, Julijana and Trpković, Andreja and Jevremović, Danimir P. and Isenović, Esma R.", year = "2019", abstract = "Cardiovascular (CV) diseases are the most common health problems worldwide, with a permanent increase in incidence. Growing evidence underlines that insulin-like growth factor 1 (IGF-1) is a very important hormone responsible for normal CV system physiology. IGF-1 is an anabolic growth hormone, responsible for cell growth, differentiation, proliferation, and survival. Despite systemic effects, IGF-1 exerts a wide array of influences in the CV system affecting metabolic homeostasis, vasorelaxation, cardiac contractility and hypertrophy, autophagy, apoptosis, and antioxidative processes. The vasodilatory effect of IGF-1, is achieved through the regulation of the activity of endothelial nitric oxide synthase (eNOS) and, at least partly, through enhancing inducible NOS (iNOS) activity. Also, IGF-1 stimulates vascular relaxation through regulation of sodium/potassium-adenosine-triphosphatase. Numerous animal studies provided evidence of diverse influences of IGF-1 in the CV system such as vasorelaxation, anti-apoptotic and prosurvival effects. Human studies indicate that low serum levels of free or total IGF-1 contribute to an increased risk of CV and cerebrovascular disease. Large human trials aiming at finding clinical efficacy and outcome of IGF-1-related therapy are of great interest. We look forward to the development of new IGF 1 therapies with minor side effects. In this review, we discuss the latest literature data regarding the function of IGF-1 in the CV system in the physiological and pathophysiological conditions. © 2019 Bentham Science Publishers.", journal = "Current Pharmaceutical Design", title = "Effects of IGF-1 on the cardiovascular system", volume = "25", number = "35", pages = "3715-3725", doi = "10.2174/1381612825666191106091507" }
Obradović, M. M., Zafirović, S., Soskić, S. S., Stanimirović, J., Trpković, A., Jevremović, D. P.,& Isenović, E. R.. (2019). Effects of IGF-1 on the cardiovascular system. in Current Pharmaceutical Design, 25(35), 3715-3725. https://doi.org/10.2174/1381612825666191106091507
Obradović MM, Zafirović S, Soskić SS, Stanimirović J, Trpković A, Jevremović DP, Isenović ER. Effects of IGF-1 on the cardiovascular system. in Current Pharmaceutical Design. 2019;25(35):3715-3725. doi:10.2174/1381612825666191106091507 .
Obradović, Milan M., Zafirović, Sonja, Soskić, Sanja S., Stanimirović, Julijana, Trpković, Andreja, Jevremović, Danimir P., Isenović, Esma R., "Effects of IGF-1 on the cardiovascular system" in Current Pharmaceutical Design, 25, no. 35 (2019):3715-3725, https://doi.org/10.2174/1381612825666191106091507 . .
Related items
Showing items related by title, author, creator and subject.
-
Plasma Induced DNA Damage: Comparison with the Effects Of Ionizing Radiation And Establishing Effective Treatment Doses
Lazović, Saša; Maletić, Dimitrije; Leskovac, Andreja; Filipović, Jelena G.; Puač, N.; Malović, Gordana N.; Joksić, Gordana; Petrović, Z. Lj. (National Symposium on Plasma Science and Technology & International Conference on Plasma Science and Technology - PLASMA 2014 (29; 2014; Kotayyam, India), 2014) -
Predicting effects of air staging application on existing coal-fired power steam boiler
Stupar, Goran; Tucaković, Dragan R.; Živanović, Titoslav; Stevanović, Žarko M.; Belošević, Srđan (Applied Thermal Engineering, 2019) -
Effects of microwave treated substrate on pepsin reaction kinetics
Pavelkić, Vesna M.; Stanisavljev, Dragomir R.; Gopčević, Kristina; Beljanski, Vladimir (Society of Physical Chemists of Serbia, 2008)